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Summary
Activated T-lymphocytes can migrate through the blood-brain barrier (BBB) and are able to invade the
central nervous system (CNS). In the present study, we investigated whether disruption of the BBB
leads to enhanced T-cell migration into the CNS. Amyloid-beta peptide 25-35 (Aβ) or tumor necrosis
factor-alpha (TNFα) were administered into the right common carotid artery of adult male Wistar rats.
The agents were administered either alone, or were followed by a cell suspension of exogenously acti-
vated T-cells. Rats of other groups received activated or non-stimulated T-lymphocytes only. Sagittal
brain sections were analyzed with immunohistochemistry of CD3 to reveal the presence of T-lympho-
cytes within the CNS parenchyma. Administration of activated T-cells alone led to T-cell migration
into the brain. Infusion of either substances (Aβ or TNFα) resulted in T-cell invasion of the CNS even
when no exogenous T-cells were added. Infusion of either of the agents together with T-lymphocytes
generated a more intense T-lymphocyte migration than in the other groups. Electron microscopic anal-
ysis and Evans-blue extravasation studies confirmed parallel disruption of the BBB. Our study demon-
strates that Aβ and TNFα induce enhanced T-lymphocyte migration towards the brain. This effect may
be attributed at least partly to dysfunctioning of the BBB, but other mechanisms are also possible. 
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Introduction
Although the central nervous system (CNS) is consid-
ered to be an immunologically privileged site (Barker
and Billingham, 1977; Hauser et al., 1983; Hickey et al.,
1985), the interpretation of this concept has been chal-
lenged recently. Data suggest that even under normal
conditions there is a moderate traffic of haematogenous
cells through the blood-brain barrier (BBB; Wekerle et
al., 1986; Hickey, 1999; Becher et al., 2000). In
immune-mediated illnesses of the CNS, cells of the
immune system are permitted to enter the brain in large
numbers (Paterson and Day, 1982; Hickey et al., 1985;
Traugott et al., 1985; Lassmann et al., 1986; Hickey and
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Kimura, 1987). Both in multiple sclerosis (MS) and in
experimental allergic/autoimmune encephalitis (EAE),
T-lymphocytes have been found in brain parenchyma
during the acute phase of the illness (Traugott, 1985;
Lassmann et al., 1986), and it was pointed out that
leukocyte entry into the CNS is one of the earliest
events in the pathogenesis of immune-modulated neuro-
logical diseases (Traugott et al., 1985). 
Numerous studies investigated the circumstances
under which T-lymphocytes can enter the CNS. Intra-
venous injection of activated T-cells specific for myelin
basic protein (MBP) can induce EAE in rats (Ben-Nun
A et al., 1981; Wekerle et al., 1986). Furthermore, it has
been proven that activated T-cells are able to enter the
CNS even when their activity has been induced by an
antigen that does not have a CNS origin. At the same
time, non-stimulated T-cells may cross the BBB only in
virtually non-detectable amounts. Therefore, it was con-
cluded that T-lymphocyte entry into the brain depends
primarily on the activation state of the cells (Wekerle et
al., 1986; Hickey et al., 1991; Westland et al., 1999). A
hypothesis has been formulated to explain how inflam-
mation develops across an intact BBB (Hickey et al.,
1991), but inflammation is always accompanied by a
dysfunctioning BBB in neuroimmunological illnesses
of the CNS. Thus, events at the BBB are of great impor-
tance in these processes (Wekerle et al., 1986; Lass-
mann et al., 1991; Owens et al., 1998). 
The aim of the present study was to investigate
whether disruption of the BBB leads to enhanced T-cell
migration towards the CNS. We studied effects of the
pharmacological agents beta-amyloid peptide (Aβ) and
tumor necrosis factor-alpha (TNFα) on the entry of T
lymphocytes into the CNS in rats. TNFα is a pro-
inflammatory cytokine known to be released in
response to infections, trauma or in neurological dis-
eases. Recent studies investigating the effects of TNFα
on the BBB described distinct changes in the permeabil-
ity of the BBB following TNFα administration. In
rodents, intravenous infusion and pial superfusion of
TNFα led to enhanced BBB permeability (Tsao et al.,
2001; Mayhan, 2002). At the same time, in vitro experi-
ments provided additional support by showing that the
permeability of cerebromicrovascular endothelial cell
monolayers was increased for markers of different
molecular weight after exposure to TNFα (Mark and
Miller, 1999).
Interestingly, TNFα also promoted lymphocyte traf-
ficking throughout the BBB. Both adhesion and trans-
migration of T-cells were shown to be stimulated by
TNFα (Lossinsky et al., 1991; McCarron et al., 1993;
Wong et al., 1999). For example, TNFα treatment
remarkably upregulated expression of the adhesion
molecule ICAM-1 in brain-derived endothelial cells,
which coincided with increased T-cell attachment
(McCarron et al., 1993). Parallel morphological studies
described that T-cells migrated across CNS endothelium
by extending finger-like projections into the endothelial
cytoplasm and moving either through the endothelial
cytoplasm or along intercellular junctions (Lossinsky et
al., 1991; Wong et al., 1999). Thus, TNFα was shown to
open up the BBB for circulating macromolecules and
stimulate transmigration of T-lymphocytes as well. 
Similar effects of Aβ on the BBB have been
observed. Aβ is a toxic agent accumulating in the form
of senile plaques in Alzheimer brains and can also occur
in the circulation (Seubert et al., 1982; Hardy and Hig-
gins, 1992; Greenberg et al., 2000; Ertekin-Taner et al.,
2001). In order to determine whether Aβ can induce
BBB leakage, Aβ fragments such as Aβ(1–40) or
Aβ(1–42) were infused either intravenously, or directly
into the carotid arteries of rats. As a result, substantial
IgG staining and massive Evans blue extravasation was
observed in brain parenchyma indicating BBB leakage
(Jancsó et al., 1998; Su et al., 1999).
Clear evidence does not yet exist that Aβ can usher
the entrance of circulating leukocytes into brain
parenchyma. However, compelling results were
obtained by employing an in vitro BBB model. The
experiments showed that Aβ(1–42) induced TNFα
secretion by human monocytes, and facilitated mono-
cyte transmigration through the constructed BBB model
(Fiala et al., 1998). A follow-up study identified not
only monocytes but also T-cells in cerebral perivascular
spaces of Alzheimer’s disease brains (Fiala et al., 2002).
These data indicate that Aβ may be able to induce infil-
tration of leukocytes and possibly T-cells into the CNS
in addition to its capacity to open up the BBB. Since
there is evidence that Aβ also induces an inflammatory
reaction in the brain and may cause the release of vari-
ous cytokines including TNFα (Barger et al., 1995;
Meda et al., 1995; Forloni et al., 1997; McRae et al.,
1997), comparison of the effects of these 2 compounds
may provide additional evidence of mechanisms of
lymphocyte trafficking into the brain.
Material and methods
Animals and surgical procedures
Adult male Wistar rats (300–350 g) were assigned to 
6 experimental groups. Each group contained 5 animals,
one animal for each survival time. The animals were
anaesthetized with chloralose-urethane solution 
(50 mg/kg α-chloralose; Sigma, St. Louis MO, USA –
1 g/kg urethane; Hungaropharma, Budapest, Hungary)
administered intraperitoneally. Rectal temp was deter-
mined continuously with a rectal thermometer and was
maintained between 37.0 °C and 37.5 °C with a ther-
mophore. 
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Amidline incision was made on the neck followed by
tracheotomy and trachea cannulation. The right com-
mon carotid artery was exposed and a fine polyethylene
cannula (PE 10) was inserted in the vessel. The pharma-
cological compounds and/or cell suspensions (see
below) were introduced via the cannula in a total vol-
ume of 1 ml, at a rate of 0.1 ml/min. Cell suspensions
were administered at 10 min after infusion of the phar-
macological compounds. The experimental groups and
the compounds that were administered are listed in
Table 1. After a survival time of 30 min, 1, 2, 3 or 4 h,
animals were perfused transcardially with phosphate-
buffered saline (PBS) followed by 4% paraformalde-
hyde (PFA in 0.1 M PBS, pH 7.4). The brains were
removed and postfixed in the fixative for 24 h at 4 oC.
Three additional animals were perfused with PBS
followed by 2% PFA and 2.5% glutaraldehyde for elec-
tron microscopical analysis. Two more animals received
Evans blue dye (Sigma) intravenously (50 mg/kg) at 
20 min before administration of Aβ or TNFα to show
their effects on the permeability of the BBB. Extravasa-
tion of Evans blue-albumin-complexes was revealed by
fluorescence microscopy (Nikon, Tokyo, Japan). 
Pharmacological agents and cell suspensions
Amyloid β-peptide (25–35) (Aβ) was a gift of Prof. B.
Penke. The peptide was solubilized in 1–2 drops of 35%
acetonitrile and then diluted in PBS. One ml aliquots of
10–3 M Aβ were frozen and stored at –20 °C until use.
Twenty four h before infusion, the aliquot was thawed
and aged for 24 h at 4 °C. Before administration, the
aliquot was diluted to a concentration of 5 × 10–4 M and
the solution was infused into the right common carotid
artery in a volume of 1 ml at a rate of 0.1 ml/min. 
Tumor necrosis factor-alpha (TNFα; human recom-
binant; Sigma) was solubilized in PBS. Animals
received an intracarotid infusion of 2.5 µg/kg TNFα in
1 ml total volume at a rate of 0.1 ml/min. 
Cell suspensions of allogenic Wistar rat spleen were
prepared in RPMI 1640 medium containing 10% heat-
inactivated fetal bovine serum and incubated in a CO2
incubator. Cells were stimulated with 10 µg/ml phyto-
hemagglutinin (PHA; Sigma) for 48 h. After incubation,
a suspension of 5–10 × 106 cells/ml was prepared in
RPMI 1640 medium containing 1% inactivated rat
serum. Cell suspensions were cultured in the same way
without PHA-stimulation and served as controls. 
To demonstrate the presence of T-lymphocytes in the
splenocyte suspension and to assess their approximate
number, we employed flow cytometric analysis. Flow
cytometry was performed on a FACStar Plus cell sorter
(Becton Dickinson, San Diego CA, USA) with FITC-
conjugated mouse anti-rat CD3 monoclonal antibodies
(Becton Dickinson). The analysis was carried out on 10,
000 cells using the CellQuest 3.1 program (Becton Dick-
inson). Control measurements, where no antibody was
added to the cells did not produce fluorescence. When
incubated with FITC-conjugated anti-CD3 antibodies, the
cell cultures showed CD3 expression in 20.3% of the
cells and 48.4% of the lymphocytes. This means that sus-
pensions of 5–10 × 106 splenocytes per ml contained
approx. 1–2 × 106 T-lymphocytes per ml. Absence of flu-
orescence when mouse IgG1 or mouse serum were added
indicated that nonspecific antibody binding did not occur.
Immunohistochemical analysis
Postfixed brains were embedded in paraffin and 4-µm-
thick serial sagittal sections were cut. After deparaf-
finization and endogenous peroxidase blockade we used
target retrieval solution (Dako, Glostrup, Denmark) for
antigen retrieval. Nonspecific binding sites were blocked
with skim milk powder. Sections were then incubated in
the presence of the primary antibody (rabbit anti-human;
Dako). The secondary antibody was horseradish peroxi-
dase-conjugated anti-rabbit (EnVisionTM; Dako). Peroxi-
dase activity was visualized using DAB. Cell nuclei were
counterstained with haematoxylin. 
Sections from the brain of one animal were analyzed
semiquantitatively in each group. Ten sections from
each brain were examined and T-cells in brain
parenchyma were counted using a light microscope
(E600; Nikon). Brain regions examined included cor-
tex, diencephalon, hippocampus, mesencephalon, olfac-
tory tract and pineal gland. Numbers of T-lymphocytes
were evaluated using repeated measurement ANOVA.
Electron microscopical analysis
Additionally, 3 rat brains were prepared for electron
microscopical analysis. The animals received a unilater-
al intracarotic infusion of either PBS, TNFα or Aβ
according to the protocol above without infusing exter-
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Table 1. Experimental groups and compunds admnistered into
the right common carotid artery
Groups Agents
PHA– 1 ml non-stimulated lymphocyte suspension
PHA+ 1 ml PHA-stimulated lymphocyte suspension
Aβ- 1 ml 5 × 10–4 M amyloid β-peptide
TNFα- 2.5 µg/kg TNFα in 1 ml volume
Aβ/PHA+ 1 ml 5 × 10–4 M amyloid β-peptide followed by
1 ml PHA-stimulated lymphocyte suspension
TNFα/PHA+ 2.5 µg/kg TNFα in 1 ml followed by 1 ml
PHA-stimulated lymphocyte suspension
nal lymphocytes. After a 2 h-survival time, rats were
transcardially perfused with PBS followed by a solution
of 2% paraformaldehyde and 2.5% glutaraldehyde in
0.1 M PBS (pH 7.4). Brains were removed and stored
overnight in fixative at 4 °C.
The hippocampus and frontoparietal cortex of the
ipsilateral hemisphere, and the pineal gland were pre-
pared for embedding. Samples were dehydrated and
embedded in Durcupan epoxy resin (Fluka, Buchs,
Switzerland). Semi-thin sections were cut on an ultra-
microtome (Ultracut E; Reichert-Jung) and stained on
microscopic object glasses with a 1:1 mixture of methy-
lene blue and Azure II blue. Samples were subsequently
coverslipped with DPX and analyzed under a light
microscope (E600; Nikon). Ultrathin sections were cut
and collected on 200-mesh copper grids. Preparations
were then contrasted with 5% uranyl-acetate and
Reynolds lead-citrate solution. Finally, samples were
analyzed using a TM10 transmission electron micro-
scope (Philips, Eindhoven, The Netherlands) and the
ultrastructural features of the BBB were characterized.
Results
Immunohistochemistry
Fluorescence microscopy showed extravasation of
Evans-blue-albumin-complexes into the nervous tissue
after administration of TNFα or Aβ (Fig. 1).
Immunofluorescence of the Evans-blue dye verified
disruption of the BBB after administration of both
TNFα and Aβ. Infiltration of the dye into the CNS was
not detected in the control group, which indicates the
presence of an intact BBB.
Sagittal brain sections labelled with anti-CD3-anti-
bodies were analyzed for T-cell invasion. In sections
showing CD3 positivity, most T-lymphocytes were
found in the subpial cortical grey matter, in perivascular
spaces, in specific groups deeper in the brain parenchy-
ma and in periventricular regions. The subarachnoid
space and the pineal gland – regions without BBB –
contained numerous T-cells in each group – except
when non-stimulated T-lymphocytes were administered
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Fig. 1. Evans-blue extravasation in the brain at 30 min after Aβ25–35-infusion into the right common carotid artery. A. Macro-
scopic appearance of Evans-blue extravasation. B, C. Fluorescence of Evans-blue dye around a cerebral vessel after extravasa-
tion. Magnifications, B, ×20; C, ×40.
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Fig. 2. Photomicrographs of CD3-positive T-lymphocytes in rat brain. A. T-cells in the subpial cortex at 30 min after TNFα
treatment. B. Subpial T-lymphocytes at 60 min after Aβ-infusion. C. Perivascularly localized T-lymphocytes in the cortex at 60
min after infusion of TNFα and an exogenous T-cell suspension. D. T-lymphocytes around a cortical blood vessel at 4 h after
treatment with Aβ and administration of a T-cell suspension. E. T-cells in the olfactory tract at 3 h after infusion of TNFα. F. T-
lymphocytes in the diencephalon at 4 h after infusion of Aβ. Magnification, ×40.
alone. Regional distribution patterns of T-cells were
similar in all groups, when T-cells were present in the
CNS. 
After administration of nonstimulated T-lymphocytes
(group PHA-), lymphocytes were not found in CNS
parenchyma. 
As expected, activated T-lymphocytes penetrated
into the CNS. Sections from group PHA+ showed CD3-
positive cells scattered in the brain parenchyma. Com-
parison of the results of groups PHA+ and PHA- indi-
cated that activated T-lymphocytes entered the CNS,
whereas non-stimulated T-cells were unable to infiltrate
brain parenchyma (Fig. 3). 
T-cells were also found in various regions of the CNS
when Aβ was administered alone (group Aβ-; Fig. 2B,
2F). Similarly, T-cells were detected intracerebrally
after TNFα injection when an exogenous cell suspen-
sion was not administered (group TNFα-; Fig. 2A, 2E).
Interestingly, both Aβ treatment and TNFα treatment
resulted in T-cell invasion into the CNS even when an
exogenous T-cell suspension was not administered. T-
cells were scattered in similar brain regions in both
cases. The numbers of cells found in the CNS were
moderately higher in the Aβ-group, especially at the
2nd and 3rd h postinjection (Fig. 3).
CD3-positive cells were also detected in the CNS
when administration of Aβ was followed by an infusion
of exogenous PHA-activated T-lymphocytes (group
Aβ/PHA+; Fig. 2D). The T-cell distribution pattern was
similar to that in case of TNFα infusion. Administration
of TNFα and exogenous activated T-lymphocytes
(group TNFα/PHA+) resulted in T-cell invasion in
perivascular spaces (Fig. 2C) and in brain parenchyma. 
When Aβ and activated exogenous T-cells were
infused together, T-cells were already found at 30 min
after infusion of the cell suspension. Afterwards, num-
bers of T-lymphocytes continued to increase and were
highest at 4 h after infusion. In the 3rd and 4th h postin-
jection, numbers of T-cells in brain parenchyma exceed-
ed numbers of T-cells when either Aβ alone or activated
T-cells alone were administered (Fig. 3B).
Fig. 3A shows that the number of T-cells found in the
CNS was highest during the first h postinjection when
TNFα and activated T-lymphocytes were infused
together. Subsequently, the number of T-cells levelled
off and was similar to that found in the TNFα- and the
PHA+ group. Thus, in the first h, administration of
TNFα and exogenous T-lymphocytes resulted in a
stronger T-cell invasion into CNS parenchyma, than
after either TNFα treatment alone or administration of
activated T-lymphocytes alone. The brain regions where
most of the T-cells were found were similar to those in
the other groups. 
Electron microscopy
Samples of the ipsilateral hippocampus, frontoparietal
cortex and pineal gland of one representative animal per
group were analyzed by electron microscopy. Since the
infused compounds affect permeability and/or integrity
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Fig. 4. Swelling of perivascular astrocytic end feet in rat hip-
pocampus after unilateral intracarotic infusion of saline (A,
B), TNFα (C, D) and beta-amyloid25–35 (E, F), as shown in
semi-thin (A, C, E) and ultrathin (B, D, F) sections. Asterisk,
microvascular lumen; a, astrocytic perikaryon; e, microvascu-
lar endothelial cell. Arrowheads indicate perivascular astro-
cytic end feet. Magnifications, A, C, E, ×100; B, D, F, ×7200.
Fig. 3. Time-related alterations in numbers of T-cells per unit
area in rat brain. Each symbol depicts the T-cell concentration
in the brain as mean (± SEM) of 10 sagittal sections of 1 rat.
Repeated measurement ANOVA indicated significant time-
dependent and group-related changes (p < 0.001±±). A. TNFα
treatment. B. Aβ treatment. *, PHA- × PHA+; +, PHA- ×
TNFα-/Aβ-; #, PHA- × TNFα+/Aβ+.
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of the BBB, we focused on the ultrastructure of cerebral
arterioles and capillaries.
The most obvious morphological change observed in
semi-thin sections was the presence of extensive lacu-
nae surrounding microvessels in both hippocampus and
frontoparietal cortex after TNFα and Aβ25–35 infusion
(Fig. 4C, E). The lacunae were identified by electron
microscopy as swelling of perivascular astrocytic end
feet (Fig. 4D, F). Astrocytic end feet adjacent to the vas-
cular basement membrane covered an increased sur-
face, contained swollen mitochondria in an empty-look-
ing cytoplasm characterized by low electron density
after treatment with TNFα and Aβ. Not only end feet
but also perikaryon and proximal processes of astro-
cytes had a swollen appearance.
An irregular luminal endothelial surface characterized
TNFα- and Aβ25–35-treated animals. Moreover, endothe-
lial cells were swollen, contained a higher amount of
pinocytic vesicles and showed occasionally loosened
tight junctions particularly after Aβ25–35 infusion.
Discussion
The present study has characterized T-cell entry into the
CNS in relation to the activated state of lymphocytes
and disruption of the BBB. Administration of exoge-
nously activated T-cells alone without disruption of the
BBB resulted in T-cell infiltration into brain parenchy-
ma. Since the antigen used for activation of T-lympho-
cytes was not of CNS origin, such as the frequently used
myelin basic protein, the activated state of the lympho-
cytes rather than antigen specificity appeared to be
important for CNS entry. In this respect, our data are in
line with previous reports suggesting that activated T-
cells can penetrate the CNS irrespective of their antigen
specificity or T-cell phenotype (Hickey et al., 1991).
The main goal of the present study was to show
whether disruption of the BBB facilitates entry of acti-
vated T-cells into brain parenchyma. We have used 2
agents, TNFα and Aβ25–35, to disrupt the BBB. Interest-
ingly, both compounds produced moderate T-cell infil-
tration into the brain when exogenous lymphocytes were
not added. Since non-activated T-cells cannot penetrate
the BBB (Merrill and Benveniste, 1996), either infused
TNFα and Aβ25–35 or disruption of the BBB itself prime
naive T-cells and facilitate their migration through the
BBB. In line with this finding, TNFα in combination
with interleukins has been shown to recruit naive T-lym-
phocytes into the liver (Abrignani, 1998), whereas the
presence of Aβ as an infectious agent in the circulation
can also stimulate T-cells (Trieb, 1996). However, the
damage imposed on the BBB may also contribute to T-
cell stimulation for reasons described below.
T-cell counts after TNFα infusion were comparable
with T-cell counts after administration of activated T-
cells alone, whereas Aβ25–35 produced a more distinct
increase in T-cell numbers. Therefore, we assume that
particularly Aβ infusion imposed such an acute damage
to the BBB as was also demonstrated by our electron
microscopical study, that it set off a neuroimmune reac-
tion involving T-cells. This suggestion is supported by
studies investigating immune responses following cere-
brovascular events. For example, experimental cerebral
ischaemia or stroke which are accompanied by BBB
disruption caused accumulation of T-cells in the affect-
ed brain region (Schroeter et al., 1994; Jander et al.,
1995; Bona et al., 1999; Campanella et al., 2002). How-
ever, these experiments identified neuronal injury rather
than BBB damage as initiator of T-cell infiltration.
Along this line, neuronal damage itself with an intact
BBB also caused T-cell aggregation at the injured CNS
site (Raivich et al., 1998). A possible mechanism of Aβ-
induced T-cell entry through an intact BBB may involve
induction of adhesion molecules such as ICAM and
VCAM, which facilitate peripheral monocyte transmi-
gration through cultured brain endothelial cell monolay-
ers (Giri et al., 2000, 2002). Therefoe, the cerebrovascu-
lar event induced in our study may have had similar
consequences with respect to neuroimmune reactions as
focal cerebral ischaemia or stroke.
Our data demonstrate that a combination of TNFα or
Aβ25–35 with primed exogenous T-cells most effectively
accelerated T-cell entry into forebrain structures. These
findings support our original hypothesis that BBB dis-
ruption can promote activated T-cell infiltration into the
CNS. However, the temporal pattern of T-cell infiltra-
tion appeared to be inverse when comparing the effects
of TNFα and Aβ25–35. TNFα caused strongest T-cell
accumulation at 30 min after infusion, whereas Aβ25–35
showed a delayed action with a peak at 4 h. These com-
plementary data confirm the suggestion of Rhodin and
Thomas (2001) that the inflammatory process set off by
circulating Aβ is mediated by TNFα. Experiments lead-
ing to this conclusion showed prevention of Aβ-induced
leukocyte invasion into peripheral tissue by administra-
tion of TNFα-binding protein (Sutton et al., 1999;
Rhodin and Thomas, 2001). Moreover, the temporal
pattern of Aβ-induced leukocyte migration appeared to
be similar to that found in our study. 
Since Aβ is known to be a prominent neurotoxic pep-
tide playing a central role in Alzheimer’s disease, our
data may have implications in the aetiology of such
neurodegenerative disorders. A recent study demon-
strated that besides monocyte/granulocyte infiltration,
T-lymphocytes frequently occurred in Alzheimer brains
(Fiala et al., 2002). Because Alzheimer’s disease is
linked with an array of neuroinflammatory signals
(Akiyama et al., 2000; Cooper et al., 2000), the results
presented here may contribute to the understanding of
cerebral inflammatory processes induced by Aβ.
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